PHOSPHA 250 NEUTRAL
Generic: DIBASIC SODIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE AND MONOBASIC SODIUM PHOSPHATE
Basic Information
Manufacturer
Rising Pharma Holdings, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
ORAL
FDA Set ID
9432adfc-6add-4ab4-ae93-2e2daf348be2
Indications & Usage
INDICATIONS AND USAGE PHOSPHA 250 TM NEUTRAL increases urinary phosphate and pyrophosphate.
As a phosphorus supplement, each tablet supplies 25% of the U.S.
Recommended Daily Allowance (U.S.
RDA) of phosphorus for adults and children over 4 years of age.
As a phosphorus supplement, each tablet supplies 25% of the U.S.
Recommended Daily Allowance (U.S.
RDA) of phosphorus for adults and children over 4 years of age.
Adverse Reactions
ADVERSE REACTIONS: Gastrointestinal upset (diarrhea, nausea, stomach pain, and vomiting) may occur with phosphate therapy.
Also, bone and joint pain (possible phosphate-induced osteomalacia) could occur.
The following adverse effects may be observed (primarily from sodium or potassium): headaches; dizziness; mental confusion; seizures; weakness or heaviness of legs; unusual tiredness or weakness; muscle cramps; numbness, tingling, pain or weakness of hands or feet; numbness or tingling around lips; fast or irregular heartbeat; shortness of breath or troubled breathing; swelling of feet or lower legs; unusual weight gain; low urine output; unusual thirst.
To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc., at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Also, bone and joint pain (possible phosphate-induced osteomalacia) could occur.
The following adverse effects may be observed (primarily from sodium or potassium): headaches; dizziness; mental confusion; seizures; weakness or heaviness of legs; unusual tiredness or weakness; muscle cramps; numbness, tingling, pain or weakness of hands or feet; numbness or tingling around lips; fast or irregular heartbeat; shortness of breath or troubled breathing; swelling of feet or lower legs; unusual weight gain; low urine output; unusual thirst.
To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc., at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.